ScreenPoint Medical has announced that its Transpara breast AI has surpassed 5 million mammograms, including over 1 million Tomosynthesis (3D) exams analyzed in support of radiologists reading mammography exams. The company will showcase its Transpara results at the upcoming 109th Annual Radiological Society of North America (RSNA) meeting, RSNA 2023, November 26-30, at McCormick Place in Chicago, IL. Image courtesy: ScreenPoint Medical
November 22, 2023 — ScreenPoint Medical has announced that its Transpara breast AI has surpassed 5 million mammograms, including over 1 million Tomosynthesis (3D) exams analyzed in support of radiologists reading mammography exams.
In a Nov. 21 statement detailing the milestone, Transpara reported that the company provides radiologists with a 'second pair' of eyes helping detect cancers earlier and reduce recall rates. Further, it noted, used by hundreds of sites globally, Transpara has set the standard for Breast AI, supporting all major mammography gantry manufacturers, and integrating into radiology reading workflow — both in the single-reading and double-reading environments.
ScreenPoint plans to showcase its Transpara results at the upcoming 109th Annual Radiological Society of North America Scientific Assembly and Annual Meeting, RSNA 2023, November 26-30, 2023 (South Hall #3947) being held at McCormick Place in Chicago, IL.
The clinical and workflow benefits of Transpara on improving the mammography screening process have been the subject of several major research studies published in top-tier peer-reviewed publications throughout the year, offered the statement. One of those included a recent journal Radiology publication (Lauritzen, et al) in August 2023. The published study, "Assessing Breast Cancer Risk by Combining AI for Lesion Detection and Mammographic Texture," demonstrated that Transpara combined with two other measures delivered a superior short term risk measure relative to many current models (i.e., Gail, TC8).
"As the most widely utilized Breast AI in clinical practice with 5 million mammograms and 1 million tomosynthesis exams analyzed, we are very proud that study after study continues to demonstrate the value that Transpara brings to breast health care provider and patients,” said Mark Koeniguer, ScreenPoint Medical CEO. “Regardless of country, patient age, breast density, or patient ethnic background, Transpara delivers consistent results. Our in-development offerings will continue to expand the reach and impact of Transpara Portfolio in helping radiologists detect cancer earlier and safely reduce workload," he added.
Transpara is FDA cleared and has European regulatory approval (CE Mark) for use with 2D and 3D mammography from multiple manufacturers. Used by hundreds of leading centers in more than 30 countries, Transpara is designed to work concurrently with radiologists, according to the company. Research shows that up to 45% of interval cancers can be found earlier using Transpara, while helping to reduce workload and optimize workflow.
More information: www.screenpoint-medical.com
Reference: https://pubs.rsna.org/doi/10.1148/radiol.230227
Related content:
Find and follow more of ITN's RSNA23 news conference coverage here
February 13, 2026 
